Your GLP-1 Is Doing More to Your Brain Than You Think

Most people who go on a GLP-1 drug are told it will reduce their appetite, and it does, but the same receptor system that turns down your hunger also sits inside the part of your brain that generates desire for everything else in your life, and most prescribers are not talking about that.

To understand why, you need the full map first.

Your brain runs a reward circuit that evolved to make you pursue things that keep you alive and reproducing. The engine of that circuit is dopamine, and the region that produces most of it is called the ventral tegmental area, or VTA, which sits deep in the midbrain and sends dopamine signals outward to regions involved in motivation, anticipation, and drive. When that dopamine flows, you want things. You initiate. You pursue. That is not a side effect of being alive, that is the mechanism your brain uses to direct your behavior toward things that matter.

Now add GLP-1 receptors into that picture. GLP-1, which stands for glucagon-like peptide-1, is a hormone your gut releases after eating, and it signals to your brain that you have had enough. The drugs modeled on it work by activating those same receptors more strongly and for longer than the natural hormone does. The receptors are expressed in the hypothalamus, which handles hunger, but they are also expressed directly inside the VTA, sitting right at the source of the dopamine signal.

A 2025 study published in Science Advances mapped exactly what happens when those VTA receptors get activated. The GLP-1 receptors do not sit on the dopamine neurons directly. They sit on a class of inhibitory neurons called GABA neurons, which are essentially the brakes in the circuit, and activating GLP-1 receptors increases the firing rate of those GABA neurons, which then suppress the dopamine neurons downstream. The result is reduced dopamine output and reduced reward-seeking behavior. The researchers demonstrated this using cocaine-seeking as the behavioral measure, not because cocaine is the point, but because cocaine-seeking is one of the clearest and most measurable signals of motivated reward pursuit available in a lab setting.

So the drug is pressing the brake on your brain's drive system as a byproduct of pressing the brake on appetite, because those two things share the same infrastructure.

Here is where it gets more specific, and more useful. A separate line of research has drawn a distinction between two components of desire that most people treat as one thing. Researchers call them "wanting" and "liking." Wanting is the anticipatory drive, the pull toward a reward before you have it, the mental space it takes up, the behavior of initiating and seeking. Liking is the hedonic response when the reward actually arrives, the pleasure of the experience itself. These two things feel like the same thing from the inside, but they are generated by different neural mechanisms and they can be separated.

A 2025 study on semaglutide found that the drug reduced reward-collection behavior, which is the wanting side, but did not diminish the hedonic liking response. In fact, the study found enhanced VTA dopamine activity during the consummatory phase, meaning once the reward was actually happening, the dopamine signal was preserved or even slightly elevated. The drug was specifically dampening the drive to pursue while leaving the experience of pleasure intact.

This is why the effect is so hard to notice from inside it. If the drug made things feel bad, your brain would register that and you would know something changed. But if things still feel fine when they happen, and you just happen to be initiating less, seeking less, thinking about it less, your brain has no negative signal to report. You do not feel wrong. You just stop doing things, and you do not connect the two.

The dopamine pathway is probably not the only mechanism at work here. A 2025 clinical review proposed that GLP-1 agonists may also upregulate activity at a serotonin receptor called 5-HT2C, which is the same receptor responsible for sexual side effects on SSRIs. The review notes this effect may be partly masked in practice because many people on GLP-1 drugs are also losing significant weight, which tends to improve mood, energy, and in some cases sexual function, so the two effects can cancel each other out and obscure what the drug is doing neurologically. The mechanism here is theoretical rather than directly demonstrated in human trials, but the receptor pharmacology supports the possibility, and the clinical pattern is consistent with it.

One controlled study did attempt to test this directly by giving dulaglutide to healthy eugonadal men in a randomized, double-blind, placebo-controlled crossover design for four weeks. They found no change in sexual function scores. That null result is worth noting, but it may reflect the study's limitations rather than the absence of an effect. Dulaglutide has weaker central nervous system penetration than semaglutide and retatrutide, the duration was four weeks, and the population was healthy men without obesity, who would not have the confounding weight-loss effect masking or amplifying anything.

The reversibility piece matters here. These drugs have a half-life of roughly one week, so by four to five weeks after stopping, the receptor activation is essentially gone and the downstream signaling returns to baseline. This is not a permanent rewiring. The effect exists while the drug is active and resolves when it clears.

What that means practically is that if someone on a GLP-1 has become less interested in sex, or less motivated to pursue hobbies, or less likely to initiate social plans, the question to ask is not what changed about that person. The question is what the drug is doing to the VTA, because the same mechanism that makes a drug good at killing appetite can also quiet the brain's signal for wanting anything at all, and the reason no one notices is exactly the reason it works, because turning down wanting does not make the present moment feel bad.

---

References

1. Merkel R, Thapa N, Engel L, et al. 2025. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Science Advances, 119, eadr5051. Finding: GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior. Source
2. Hurst K, et al. 2025. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurobiology of Disease and Treatment. Finding: Semaglutide reduced reward collection but did not diminish hedonic "liking" response, and actually enhanced VTA dopamine activity during consummatory phase. Source
3. Gelfand SG, Tveit RL, Simon JA. 2026. Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity Pillars, 17, 100233. Finding: GLP-1 agonists likely decrease sexual desire via 5-HT2C serotonergic upregulation same mechanism as SSRIs, but this is camouflaged by competing positive effects of weight loss. Source
4. Hendershot CS, et al. 2025. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 824, 395-405. Finding: Semaglutide reduced alcohol consumption, craving, and heavy drinking days in a Phase 2 RCT n=48, confirming reward pathway modulation extends beyond appetite. Source
5. Jalleh RJ, et al. 2024. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine, 107. Finding: 4-week dulaglutide in healthy eugonadal men showed no change in sexual function scores null result, but short duration and weaker CNS penetration than semaglutide. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness